Editor: James B. Lok, University of Pennsylvania, UNITED STATES the HVR-IV and the mtDNA cox1 gene in S. stercoralis and S. fuelleborni isolated from different hosts (humans, dogs, apes, and monkeys) and from different geographical locations. The HVR-IV region was again found species-specific. In the study by Hasegawa et al. [16] , the authors described 1 within species polymorphism, which, however, occurred within the worms isolated from humans and, therefore, provided no indication of a separation of human and dog derived S. stercoralis. In contrast to this, in their earlier study, Hasegawa et al. [15] had noticed that based on a preliminary genetic analysis of the mtDNA, dog-derived S. stercoralis appeared phylogenetically distant from those of primate (including human) derived S. stercoralis. In the second study, [16] the mtDNA cox1 gene was found to be more conserved within S. stercoralis compared to S. fuelleborni. Nevertheless, based on the cox1 nucleotide sequences, S. stercoralis from dogs appeared phylogenetically separated from those isolated from humans. Further, there was 1 amino acid substitution identified, which consistently separated the admittedly rather small number of dog derived S. stercoralis from human derived S. stercoralis [16] . Genetic studies of human S. stercoralis from different geographic zones suggested that climatic conditions, such as temperature and moisture, may coincide with genetic changes [17] [18] [19] . More research examining the DNA sequences of dog and human S. stercoralis has to be done in order to improve our understanding of animal S. stercoralis infectivity to humans.
Presently, there is limited evidence regarding the role of dogs in human strongyloidiasis; however, there is enough to suggest that further research is needed to investigate this potential route of infection. Dogs carrying S. stercoralis in communities could possibly explain the limitations of previous Mass drug administration (MDA) programs; this is another area requiring further research. A study by Kearns et al. [20] investigated the prevalence of human strongyloidiasis and scabies in remote Australian Aboriginal communities to evaluate the efficacy of ivermectin MDA. The study demonstrated that ivermectin MDA reduced prevalence but failed to eliminate strongyloidiasis and scabies in the community [20] . Reappearance of strongyloidiasis could potentially be due to helminth resistance development or reinfection from environmental reservoirs (such as dogs, soil, etc.). Control of environmental reservoirs would also reduce reliance on MDA targeting humans as S. stercoralis ability to autoinfect in humans can compromise the success of the MDA, leading to potential helminth resistance development to a drug [21] . However, this would not be a concern for MDA of dogs as S. stercoralis tend to lose autoinfection ability in healthy dogs [5, 22] .
Anecdotally, animal management strategies are already being undertaken in many remote communities, and as such, concurrent treatment with anthelmintic drugs would minimise costs. Mass vaccination of dogs, including oral drug treatment targeting stray dogs, have been successfully practiced over the years to significantly decrease the rabies prevalence among humans [23, 24] . The rabies elimination model has been estimated to cost between US$2 to US $5 for a single dog vaccination, suggesting that treatment of dogs presents an economically suitable option [24, 25] . Drug treatment of water buffaloes is another successful example of MDA when applied to a potential animal reservoir to control human schistosomiasis [26] . Future MDA programs should consider treating both humans and dogs to fight strongyloidiasis. Given that the relative cost of treating dogs is low, this potentially could provide a low cost and low-risk mechanisms to reduce the risk of reinfection.
